comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 09:57:21 - browse：95797

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： The best solution to the drug shortages problem

entertainment

WSS

Medical student insurance fails on mental health care coverage

NIH trials fail to test meaningful long Covid therapies, experts say

Methadone doses haven’t kept up in the age of fentanyl

Biotech lab space demand falls sharply

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

EpiPen alternative approval delay highlights citizen petition issue

hotspot

comprehensive

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

United colonoscopy coverage change 'may cost lives,' doctors say

Anavex keeps shifting the goalposts in its clinical trials

In Memoriam: Notable people who died in 2023

FDA panel to weigh approval of NurOwn, controversial ALS drug

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A biotech analyst on neuroscience, placebo effect, not over

Hepatitis C has a cure — but many Americans still lack access to it

Hearing on Medicare drug price negotiation gets unusually heated

leisure time

Why failed clinical trials don’t always spell doom for a new drug

Maui's cultural, historic landmarks damaged in the devastating wildfires

Changes to biosimilar regulatory framework must prioritize patients

Naloxone nonprofit donates 200,000 doses after FDA approval

Wegovy trial has doctors encouraged over new possibilities

South Korea throws huge K

hotspot

focus

entertainment

hotspot